ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0663

Anti-Erythrocyte Antibodies in Childhood Onset Systemic Lupus Erythematosus

Lauren Robinson1, Zurong Wan2, Preetha Balasubramanian3, Juan Rodriguez Alcazar3, Lynnette Walters4, Jeanine Baisch2, karen onel5, Tracey Wright6, Virginia Pascual3 and Simone Caielli3, 1Hospital for Special Surgery/New York Presbyterian-Weill Cornell, New York, NY, 2Weill Cornell Medicine, New York, NY, 3Weill Cornell Medical College, New York, NY, 4Scottish Rite Hospital for Children, Allen, TX, 5Hospital for Special Surgery, New York, NY, 6UT Southwestern, Plano, TX

Meeting: ACR Convergence 2022

Keywords: Autoantibody(ies), interferon, Monocytes/macrophages, Pediatric rheumatology, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: SLE – Etiology and Pathogenesis Poster

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Systemic Lupus Erythematosus (SLE) is a disease characterized by the presence of auto-antibodies, immune complex deposition, and a robust type 1 interferon signature. It is widely known that SLE patients often have Coombs positivity, suggesting the presence of anti-erythrocyte antibodies. The presence of these antibodies in the absence of hemolytic anemia have long been thought to be clinically insignificant, though an association with a more severe disease phenotype has been reported. Recent work in pediatric SLE has implicated anti-erythrocyte antibodies in disease pathogenesis via opsonization of mitochondria-containing erythrocytes, leading to enhanced erythrophagocytosis and induction of type-1 interferon production by myeloid cells (Caielli et al., 2021). Still, little is known about anti-erythrocyte antibodies in pediatric SLE, including their prevalence, association with disease activity and phenotype, and antigenic target or specificity. The primary objective of this project is to confirm the presence of anti-erythrocyte antibodies in pediatric SLE patients. Additional objectives include characterization of the target antigens and functional properties of these antibodies, as well as to correlate their presence with disease activity and phenotype.

Methods: Serum from 8 pediatric healthy controls and 20 pediatric SLE patients was analyzed for detection of anti-erythrocyte membrane protein antibodies. Erythrocyte membrane protein lysate was generated via the creation of erythrocyte “ghost” membranes and used as a substrate for western blotting. Membranes with erythrocyte membrane proteins were probed with healthy serum or pediatric SLE serum, and the presence of IgG against erythrocyte membrane protein was revealed with anti-human IgG conjugated to HRP.

Results: 15 of 20 pediatric SLE serum samples had strongly positive IgG bands to erythrocyte protein antigens on western blot, compared to 0 of 8 healthy pediatric controls. The SLE serum samples showed reactivity against several target antigens of different molecular weights ranging from 25-250kd, and patterns of reactivity varied between samples [Figure 1]. The most prevalent immunoreactive band was at a molecular weight of 75kd (7 of 20 pediatric SLE samples). There was no correlation between the presence of anti-erythrocyte antibodies and hemoglobin or hematocrit.

Conclusion: This study supports the presence of anti-erythrocyte antibodies in a majority of patients with pediatric SLE in the absence of anemia. Future studies will focus on identifying the target erythrocyte proteins and establishing whether a correlation exists between these antibodies and the capacity to opsonize and enhance erythrophagocytosis in vitro. Our ultimate goal is to determine the role these antibodies may play in disease pathogenesis.

Supporting image 1

Figure 1: Representative western blots detecting serum antibodies against erythrocyte ghost protein lysate from 3 healthy donors. Left panel shows 2 of 8 blots from pediatric healthy controls. Right panel shows 3 of 20 blots from cSLE patients. All experiments were run in triplicate using ghost membranes from 3 independent donors. Image created with BioRender.


Disclosures: L. Robinson, None; Z. Wan, None; P. Balasubramanian, None; J. Rodriguez Alcazar, None; L. Walters, None; J. Baisch, None; k. onel, None; T. Wright, None; V. Pascual, AstraZeneca, Sanofi, AstraZeneca; S. Caielli, None.

To cite this abstract in AMA style:

Robinson L, Wan Z, Balasubramanian P, Rodriguez Alcazar J, Walters L, Baisch J, onel k, Wright T, Pascual V, Caielli S. Anti-Erythrocyte Antibodies in Childhood Onset Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/anti-erythrocyte-antibodies-in-childhood-onset-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-erythrocyte-antibodies-in-childhood-onset-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology